Piper Sandler raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $13 from $11 and keeps an Overweight rating on the shares. The firm updated the company’s model post the earnings report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Biotech Alert: Searches spiking for these stocks today
- Adaptive Biotechnologies price target raised to $9 from $7 at Morgan Stanley
- Adaptive Biotechnologies: Strong Q1 Performance but Hold Rating Due to Valuation Concerns
- Adaptive Biotechnologies Reports Strong Earnings and Strategic Growth
- Apple reports earnings beat, China weighs trade talks with U.S.: Morning Buzz